CPSE:CHR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Chr. Hansen Holding

Executive Summary

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia-Pacific. More Details


Snowflake Analysis

Acceptable track record with limited growth.


Similar Companies

Share Price & News

How has Chr. Hansen Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CHR is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CHR's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-5.5%

CHR

0.8%

DK Chemicals

-0.3%

DK Market


1 Year Return

18.4%

CHR

8.2%

DK Chemicals

25.0%

DK Market

Return vs Industry: CHR exceeded the Danish Chemicals industry which returned 7.9% over the past year.

Return vs Market: CHR underperformed the Danish Market which returned 24.7% over the past year.


Shareholder returns

CHRIndustryMarket
7 Day-5.5%0.8%-0.3%
30 Day-8.2%9.7%6.4%
90 Day-13.7%5.4%8.3%
1 Year18.4%18.4%11.8%8.2%27.3%25.0%
3 Year13.1%8.2%12.5%1.4%50.9%39.2%
5 Year55.2%43.2%46.1%24.2%53.0%33.5%

Long-Term Price Volatility Vs. Market

How volatile is Chr. Hansen Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Chr. Hansen Holding undervalued compared to its fair value and its price relative to the market?

46.62x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CHR (DKK609.8) is trading above our estimate of fair value (DKK239.07)

Significantly Below Fair Value: CHR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CHR is poor value based on its PE Ratio (46.6x) compared to the XE Chemicals industry average (20.4x).

PE vs Market: CHR is poor value based on its PE Ratio (46.6x) compared to the Danish market (17.3x).


Price to Earnings Growth Ratio

PEG Ratio: CHR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: CHR is overvalued based on its PB Ratio (12.1x) compared to the XE Chemicals industry average (1.7x).


Next Steps

Future Growth

How is Chr. Hansen Holding forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-0.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CHR's earnings are forecast to decline over the next 3 years (-0.9% per year).

Earnings vs Market: CHR's earnings are forecast to decline over the next 3 years (-0.9% per year).

High Growth Earnings: CHR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CHR's revenue (8.8% per year) is forecast to grow faster than the Danish market (6.4% per year).

High Growth Revenue: CHR's revenue (8.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CHR's Return on Equity is forecast to be high in 3 years time (21.3%)


Next Steps

Past Performance

How has Chr. Hansen Holding performed over the past 5 years?

7.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CHR has high quality earnings.

Growing Profit Margin: CHR's current net profit margins (23.9%) are lower than last year (24.4%).


Past Earnings Growth Analysis

Earnings Trend: CHR's earnings have grown by 7.9% per year over the past 5 years.

Accelerating Growth: CHR's earnings growth over the past year (1%) is below its 5-year average (7.9% per year).

Earnings vs Industry: CHR earnings growth over the past year (1%) exceeded the Chemicals industry -12.1%.


Return on Equity

High ROE: Whilst CHR's Return on Equity (25.94%) is high, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is Chr. Hansen Holding's financial position?


Financial Position Analysis

Short Term Liabilities: CHR's short term assets (€607.1M) do not cover its short term liabilities (€1.0B).

Long Term Liabilities: CHR's short term assets (€607.1M) do not cover its long term liabilities (€943.3M).


Debt to Equity History and Analysis

Debt Level: CHR's debt to equity ratio (147.7%) is considered high.

Reducing Debt: CHR's debt to equity ratio has increased from 94% to 147.7% over the past 5 years.

Debt Coverage: CHR's debt is well covered by operating cash flow (27.6%).

Interest Coverage: CHR earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Chr. Hansen Holding current dividend yield, its reliability and sustainability?

1.28%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CHR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CHR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CHR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CHR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CHR is not paying a notable dividend for the Danish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CHR's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Mauricio Graber (57 yo)

2.42yrs

Tenure

€3,369,000

Compensation

Mr. Mauricio Graber has been Chief Executive Officer, President and Member of Executive Board of Chr. Hansen Holding A/S since joining it on June 1, 2018. Mr. Graber serves as Director of Jungbunzlauer Sui...


CEO Compensation Analysis

Compensation vs Market: Mauricio's total compensation ($USD4.03M) is about average for companies of similar size in the Danish market ($USD3.34M).

Compensation vs Earnings: Mauricio's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mauricio Graber
CEO, President & Member of Executive Board2.42yrs€3.37m0.017%
€ 13.5m
Thomas Schäfer
Executive VP3yrs€745.00k0.0018%
€ 1.5m
Lise Mortensen
Executive VP0.083yrno datano data
Torsten Steenholt
Executive Vice President of Global Operations3.83yrsno datano data
Martin Riise
Head & Senior Director of Investor Relationsno datano datano data
Winnie Bügel
Corporate Vice President of Compliance & Corporate Affairs4.42yrsno datano data
Camilla Lercke
Head of Media Relationsno datano datano data
Alice Larsen
Corporate Vice President of Global Human Resources4.33yrsno datano data
Laurent Hubert
VP & Head of Foodno datano datano data
Jacob Paulsen
Executive Vice President of Food Cultures & Enzymes4.17yrsno datano data
Christian Barker
Executive Vice President of Health & Nutritionno datano datano data
Helle Rexen
Interim Head of Media Relations3.83yrsno datano data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Management: CHR's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jesper Brandgaard
Independent Vice Chairman2.83yrs€144.00k0.0035%
€ 2.8m
Dominique J. Reiniche
Independent Chairman of the Board2yrs€250.00k0.0019%
€ 1.5m
Luis Rocamora
Independent Director4yrs€93.00k0.0017%
€ 1.3m
Mark Wilson
Independent Director10.08yrs€129.00k0.0023%
€ 1.8m
Heidi Kleinbach-Sauter
Independent Director3yrs€94.00k0.00057%
€ 457.9k
Kristian Villumsen
Independent Director6yrs€76.00k0.0046%
€ 3.7m
Per Poulsen
Employee Representative Director7yrs€54.00k0.00019%
€ 152.6k
Lisbeth Grubov
Employee Representative Director3yrs€54.00k0.000090%
€ 72.3k
Charlotte Hemmingsen
Employee Representative Director3yrs€54.00k0.00083%
€ 666.8k
Kim Soerensen
Employee Representative Director3yrs€54.00k0.000020%
€ 16.1k
Niels Nielsen
Independent Director2yrs€74.00k0.00097%
€ 779.3k
Kevin Lane
Directorno datano datano data

3.0yrs

Average Tenure

57yo

Average Age

Experienced Board: CHR's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Chr. Hansen Holding A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chr. Hansen Holding A/S
  • Ticker: CHR
  • Exchange: CPSE
  • Founded: 1874
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: kr.80.337b
  • Shares outstanding: 131.74m
  • Website: https://www.chr-hansen.com

Number of Employees


Location

  • Chr. Hansen Holding A/S
  • Bøge Allé 10-12
  • Horsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CHRCPSE (OMX Nordic Exchange Copenhagen)YesShare CapitalDKDKKJun 2010
51CDB (Deutsche Boerse AG)YesShare CapitalDEEURJun 2010
0MR6LSE (London Stock Exchange)YesShare CapitalGBDKKJun 2010
CRTS.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2010
CHRCBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBDKKJun 2010
CHR NBMV (Bolsa Mexicana de Valores)YesShare CapitalMXMXNJun 2010
CHYH.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDMay 2012

Biography

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North A...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 18:04
End of Day Share Price2020/11/27 00:00
Earnings2020/08/31
Annual Earnings2020/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.